Loading stock data…
MDLN
$44.75+0.28 (+0.63%)
Market ClosedLast close May 1
Medline Inc.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$44.75
Potential Downside
38.9%
Whystock Fair Value$27.35
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus27 analysts
Buy
Mean target$53.52+19.6%
Range$45.00 – $60.00
Fundamentals
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$38.28B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
32.98
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
10.79%
Volume
Today's trading volume
2.84M
Recent News
Symbotic Medline Deal Tests AI Warehouse Platform In Healthcare Distribution
Symbotic (NasdaqGM:SYM) has signed an agreement with Medline to bring its AI powered warehouse automation system to the healthcare supply chain. This marks the first use of Symbotic's robotics and software platform in healthcare distribution, extending beyond its retail and consumer goods customers. Symbotic enters this Medline agreement with a recent share price of $59.52 and a 5 year return of about 7x. The stock has also posted a 170.5% return over the past year, while year to date...
Medline (MDLN) Partners With Symbotic to Implement AI-Powered Warehouse Automation
Medline Inc. (NASDAQ:MDLN) is one of the 10 Best New Stocks to Invest In According to Hedge Funds. Medline Inc. (NASDAQ:MDLN) is one of the best new stocks to invest in according to hedge funds. On April 16, Medline announced an agreement with Symbotic to implement AI-powered warehouse automation, making it the first healthcare company […]
Flurry of US IPOs Race to Tap Market Ahead of SpaceX Debut
(Bloomberg) -- The US IPO market has gone from desolate to bustling in a matter of weeks, with companies looking to raise as much as $17.3 billion this month alone and capitalize on stocks’ resilience.Most Read from BloombergKuwait Declares Further Force Majeure on Oil ShipmentsInside Alex Cooper’s Unwell: Tears, Screaming and Employees Looking for the ExitTrump Aims to Seal Iran Deal, Says Truce Extension UnlikelyThree Ships Including an Iranian Vessel Cross Hormuz StraitCruise Ships Seized Bri
EY on the current state of the medtech industry
OEMs continue to prioritise high-growth segments of the medtech industry such as pulsed-field ablation (PFA), while conflict in the Middle East is impacting IPO activity.
MDLN Gets FDA Warning for Quality Lapses in Angiographic Syringes
MDLN faces FDA warning over cGMP lapses in angiographic syringes, citing weak quality controls, CAPA gaps and design flaws despite escalating share price.